ライフサイエンスコーパス: adrenergic agonist

1 ications (opioids, vasopressors, and alpha-2 adrenergic agonists).

2 responses to electrical stimulation or to an adrenergic agonist.

3 ncreased metabolic responsiveness to a beta3-adrenergic agonist.

4 ncrease by a standard inhaled dose of a beta-adrenergic agonist.

5 reased as a function of the concentration of adrenergic agonist.

6 l nerve block or spinal clonidine, an alpha2-adrenergic agonist.

7 gnaling in response to injection of a beta-3 adrenergic agonist.

8 e in white adipose tissue stimulated by beta-adrenergic agonists.

9 measured from gland fragments in response to adrenergic agonists.

10 to deficient vATPase and its rescue by beta2-adrenergic agonists.

11 ts inhibitory effect can be reversed by beta-adrenergic agonists.

12 ystem auditory response properties by NE and adrenergic agonists.

13 dulation of TRPM7 activity by muscarinic and adrenergic agonists.

14 or the increase in heart rate caused by beta-adrenergic agonists.

15 Stimulated release was inhibited by alpha(2)-adrenergic agonists.

16 ips, calcium handling, and responses to beta-adrenergic agonists.

17 responds to low doses of cholinergic or beta-adrenergic agonists.

18 ectorial fluid transport in response to beta-adrenergic agonists.

19 egulating portal vein responsiveness to beta-adrenergic agonists.

20 of LTP also is modulated importantly by beta-adrenergic agonists.

21 ts of clonidine and other sympathoinhibitory adrenergic agonists.

22 nses to glutamatergic, lysophosphatidic, and adrenergic agonists.

23 the acetylcholine receptor ion channel, and adrenergic agonists.

24 e nucleotide-sensitive binding of the alpha2-adrenergic agonist, [3H]UK-14,304.

25 kers, 4.01 (CrI, 0.48 to 7.43); 1995: alpha2-adrenergic agonists, 5.64 (CrI, 1.73 to 9.50); 1999: pro

26 ly relevant airspace concentrations of beta2-adrenergic agonists a) stimulate maximal cAMP-dependent

27 this review the authors will focus on alpha2-adrenergic agonists, a new class of sedative/analgesic a

28 beta-Adrenergic agonists accelerate the clearance of alveolar

29 Our findings suggest that alpha2-adrenergic agonists act via a Gi family member on early

30 nary resuscitation were traced to the alpha1-adrenergic agonist action of epinephrine.

31 dolol exhibits approximately 60% of the beta-adrenergic agonist activity of xamoterol in normal human

32 , high Ca(2+), lysophosphatidylcholine, beta-adrenergic agonist, acylcarnitine, and the Ca(2+) ionoph

33 We have previously shown that beta-adrenergic agonists affect Na+-K+ pump current (Ip) thro

34 ings of increased risk associated with beta2-adrenergic agonist agents together with stress related t

35 ta-blockers was less common but use of beta2-adrenergic agonist agents was more common in patients wi

36 proterenol, a rapidly acting peripheral beta-adrenergic agonist akin to adrenaline, or saline.

37 We hypothesized that the inhaled beta-adrenergic agonist albuterol would improve pulmonary vas

38 the present study, we show that the alpha(2)-adrenergic agonist (alpha(2)-agonist) clonidine induced

39 nvestigate the effects of a selective alpha2-adrenergic agonist, alpha-methylnorepinephrine (alphaMNE

40 The selective alpha2-adrenergic agonist, alphaMNE, was as effective as epinep

41 Alpha2-adrenergic agonists also reduced stimulation of ERK1/2 b

42 Isoproterenol, the beta-adrenergic agonist, also elicited protein secretion at 1

43 We examined the effect of beta-adrenergic agonists and antagonists on action potential

44 tes to examine the physiological response to adrenergic agonists and beta-blocker treatment.

45 inding protein (beta ARB) is induced by beta-adrenergic agonists and binds to G-protein-linked recept

46 se activation and cFos expression induced by adrenergic agonists and biomechanical stress.

47 ysfunction, which can be prevented with beta-adrenergic agonists and cAMP.

48 In contrast, alpha(1D)-adrenergic agonists and EGF do not use Pyk2 and Src but

49 cient mice, the contractile response to beta-adrenergic agonists and extracellular calcium is reduced

50 Both beta-adrenergic agonists and insulin provoke sequestration of

51 and regulate other cellular functions, beta-adrenergic agonists and nitric oxide-containing compound

52 r smooth muscle to block the effect of alpha-adrenergic agonists and reduce vascular tone.

53 inhibitory compounds, clonidine (an alpha-2 adrenergic agonist) and muscimol (a GABAa agonist) induc

54 ouse hearts exposed to isoproterenol, a beta-adrenergic agonist, and isoproterenol-induced increases

55 nhaled corticosteroids with long-acting beta-adrenergic agonists, and anti-IgE.

56 nction measurements, responsiveness to beta2-adrenergic agonists, and health care use.

57 ction abnormalities, diminished responses to adrenergic agonists, and impaired ventricular function o

58 hemodynamic responses to bolus injections of adrenergic agonists, and intrinsic heart rate were deter

59 ponse to adenosine, prostaglandin E(2), beta-adrenergic agonists, and other mediators, is a means of

60 c anhydrase inhibitors, beta-blockers, alpha-adrenergic agonists, and prostaglandin analogues on opti

61 beta2-adrenergic agonists are an effective treatment for DOK7-

62 Inhaled beta-adrenergic agonists are the most commonly used medicatio

63 The alpha2-adrenergic agonists are unique.

64 Caffeine and beta-adrenergic agonists are well-recognised drugs that cause

65 Vascular responses to adrenergic agonists as well as endothelial dilator funct

66 dation was administered with DEX, an alpha-2 adrenergic agonist, as an intravenous bolus (2 mug per k

67 The precise mechanism of action of beta2-adrenergic agonists at the NMJ is not fully understood.

68 s system (SNS) and can be stimulated by beta-adrenergic agonists, at least in animals.

69 hite)) were administered Ractopamine (a beta-adrenergic agonist; BA; 20 ppm in feed) or Reporcin (rec

70 rs, a febrile state, vagotonic agents, alpha-adrenergic agonists, beta-adrenergic blockers, tricyclic

71 inson disease (PD) associated with the beta2 adrenergic agonist (beta2-agonist) salbutamol.

72 (Thy1-CFP mice) to determine how the alpha2-adrenergic agonist brimonidine influences loss of Thy1 p

73 Administration of beta-adrenergic agonist bronchodilators to patients with airw

74 The most promising solutions are the alpha-2-adrenergic agonists but further investigation is necessa

75 ered a Frizzled-2 chimera responsive to beta-adrenergic agonist by using the ligand-binding domains o

76 e computed bias factors for a number of beta-adrenergic agonists by comparing BRET assays of receptor

77 ttenuate responses of cardiomyocytes to beta-adrenergic agonists by decreasing PLN phosphorylation an

78 -term use of decongestant nasal spray (alpha adrenergic agonist) causes nasal congestion by rhinitis

79 Dexmedetomidine, an alpha-2-adrenergic agonist, causes a unique kind of sedation, ac

80 cold exposure and injection with the beta(3) adrenergic agonist CL 316, 243(CL)].

81 The beta(3)-adrenergic agonist CL 316,243 (CL) increased lipolysis a

82 8 h) cold stress or challenge with the beta3-adrenergic agonist CL316,243.

83 ice, as were the effects of fasting, a beta3-adrenergic agonist (CL316243), and thyroid hormone on th

84 e curves for metabolic response to a beta(3)-adrenergic agonist, CL316243, indicating normal sensitiv

85 ze reverse remodeling, followed by the beta2 adrenergic agonist clenbuterol.

86 therefore examined the effects of the alpha2-adrenergic agonist clonidine on mean arterial pressure,

87 actions were evoked by the selective alpha2 adrenergic agonist clonidine.

88 In contrast, the adrenergic agonists clonidine or norepinephrine, and the

89 phenylephrine (PHE; 0.5 mg/kg BW), an alpha2-adrenergic agonist, clonidine (CLON; 0.6 mg/kg BW), or a

90 ding leukotriene modifiers, long-acting beta-adrenergic agonists, combination inhaled corticosteroids

91 which corticosteroids and long-acting beta2 -adrenergic agonists confer protection against pathologic

92 We studied whether beta-adrenergic agonists could restore lung edema clearance i

93 sts regulate their proliferation, and a beta-adrenergic agonist decreases bone mass in leptin-deficie

94 Conversely, administering a beta2-adrenergic agonist decreases GVHD in mice housed at 30 d

95 ct of tyramine, and increased sensitivity to adrenergic agonists demonstrate dramatically disordered

96 The alpha-2 adrenergic agonist dexmedetomidine (Dex), 3-300 microg/k

97 loss of consciousness (LOC) with the alpha2-adrenergic agonist dexmedetomidine and return of conscio

98 nd to describe the application of an alpha-2-adrenergic agonist dexmedetomidine in the anesthetic man

99 s, we show that the clinically used alpha(2)-adrenergic agonist dexmedetomidine that enhances EEG slo

100 ams, 3 or 30 nmol of phenylephrine (alpha(1)-adrenergic agonist) did not alter bladder activity; wher

101 ertension induced by phenylephrine, an alpha-adrenergic agonist, did not cause AAA or rupture in Apln

102 ent of A-ZIP/F-1 mice with CL316243, a beta3-adrenergic agonist, did not increase O2 consumption.

103 s but was normalized with supply of the beta-adrenergic agonist dobutamine.

104 Together, our data reveal a new paradigm for adrenergic agonist dose-dependent cAMP/PKA activities fo

105 azolidines including analogues of the alpha2 adrenergic agonist drug clonidine is elaborated.

106 Altered vascular responses to adrenergic agonists during pregnancy are thought to play

107 , we found that sedation induced with alpha2-adrenergic agonists (e.g., dexmedetomidine) and sleep ho

108 stimuli in rat myocytes, including alpha(1)-adrenergic agonists, endothelin-1, prostaglandin F(2alph

109 Further, administration of a beta(2) adrenergic agonist enhances mobilization in both control

110 The beta-adrenergic agonist failed to elicit a significant number

111 Isoproterenol (beta-adrenergic agonist) failed to alter plasma leptin but re

112 ong-term follow-up for the addition of beta2-adrenergic agonists for a cohort of patients with acetyl

113 of either low or high doses of the alpha-2A adrenergic agonist guanfacine (GFC) to aged monkeys has

114 oxetine than for the extended-release alpha2-adrenergic agonists guanfacine or clonidine (no studies)

115 We examine the effects of the alpha2 adrenergic agonist, guanfacine HCl, on responses to stre

116 alpha-2 adrenergic agonists have been reported to decrease norep

117 beta-Adrenergic agonists have been selected as model compound

118 Alpha-2 adrenergic agonists have been useful as adjuvant for reg

119 Alpha2-adrenergic agonists have specific and selective effects

120 eatments of inhaled corticosteroids and beta-adrenergic agonists; however, 5-10% have severe disease

121 for treating hypertension over pure alpha(2)-adrenergic agonists (i.e., guanabenz) due to its lowered

122 In this study, we investigated whether beta2-adrenergic agonists improve both neurotransmission and s

123 dies are required to determine whether beta2-adrenergic agonists improve outcome in patients with acu

124 factor-alpha (TNF) as well as to an alpha(2)-adrenergic agonist in an area of the central nervous sys

125 The modulation of the exchanger by a beta-adrenergic agonist in whole-cell clamped ventricular myo

126 The working mechanism of beta2-adrenergic agonists in myasthenic patients is not fully

127 f peripheral blood mononuclear cells to beta-adrenergic agonists in patients with heart failure (HF)

128 tested a panel of combinations of opioid and adrenergic agonists in PKCepsilon knock-out mice and fou

129 hibition could potentiate the effect of beta-adrenergic agonists in the treatment of obesity and its

130 Following fasting or injection of a beta3-adrenergic agonist, in vivo lipolysis and ketogenesis we

131 beta-adrenergic agonists increase active Na(+) transport and

132 We have also previously shown that alpha-adrenergic agonists increase Ip through a protein kinase

133 adrenergic antagonists, indicating that beta-adrenergic agonists increase the metabolism of BAT.

134 Both alpha1- and beta-adrenergic agonists increase the severity of global myoc

135 The data suggest that beta-adrenergic agonists increased alveolar fluid reabsorptio

136 d in cultured cardiac fibroblasts by several adrenergic agonists, indicating that the adrenergic axis

137 Beta-adrenergic agonists induce protein kinase A (PKA) phosph

138 Phenylephrine (100 mumol/L), an alpha1 adrenergic agonist, induced upregulation of Nox4 (1.5-fo

139 n I (cTnI) contributes significantly to beta-adrenergic agonist-induced acceleration of myocardial re

140 duced activation of ERKs requires Raf, alpha-adrenergic agonist-induced activation of ERKs does not r

141 otein, is required for endothelin- and alpha-adrenergic agonist-induced cardiomyocyte hypertrophy and

142 alpha(1)-adrenergic agonist-induced hypertrophy of cardiac myocyt

143 to the lacrimal gland inhibited neurally and adrenergic agonist-induced protein secretion by 77% and

144 production by 52% and inhibited neurally and adrenergic agonist-induced protein secretion by 80% and

145 cks L-LTP; conversely, application of a beta-adrenergic agonist induces the L-LTP.

146 tent, highly specific, and long-acting beta2-adrenergic agonist, induces renal mitochondrial biogenes

147 aneous firing rate, and clonidine-an alpha2A-adrenergic agonist-inhibited LC neuronal firing less eff

148 etomidine (Dex), a potent, selective alpha-2 adrenergic agonist, injected bilaterally directly into t

149 ne temperature was seen before or after beta-adrenergic agonist injection.

150 uggest that vascular responsiveness to alpha-adrenergic agonists is maintained during postexercise hy

151 mylase secretion from parotid glands by beta-adrenergic agonists is mediated by the activation of ade

152 Dexmedetomidine, an alpha2 adrenergic agonist, is a useful sedative but can also ca

153 esponses, the sensitivity of ICa to the beta-adrenergic agonist isoprenaline (Iso) was studied in bot

154 ed the Ca(2+) current stimulated by the beta-adrenergic agonist isoprenaline (Iso), and washout of AC

155 We show that the adrenergic agonist isoprenaline promotes receptor and G

156 ogenic index, 4.10; n = 8 cells) or the beta-adrenergic agonist isoproterenol (arrhythmogenic index,

157 lipolysis in response to 10 muM of the beta-adrenergic agonist isoproterenol (by 42%), 10 muM of the

158 reshold concentration (1 nmol/L) of the beta-adrenergic agonist isoproterenol (Iso), genistein caused

159 The beta-adrenergic agonist isoproterenol (ISO; 1 muM) increased

160 n the pipette or in the presence of the beta-adrenergic agonist isoproterenol (isoprenaline; ISO).

161 Using the beta-adrenergic agonist isoproterenol as a specific pathologi

162 egrated syncytium was responsive to the beta-adrenergic agonist isoproterenol as well as to other pha

163 For comparison, the beta-adrenergic agonist isoproterenol caused a 38 % increase

164 membrane induced by cholera toxin, the beta-adrenergic agonist isoproterenol caused a rapid partial

165 on of noradrenaline or of the selective beta-adrenergic agonist isoproterenol decreased gap junction-

166 hallenge of Zmpste24(-/-) mice with the beta-adrenergic agonist isoproterenol did not trigger ventric

167 The beta-adrenergic agonist isoproterenol increased lung liquid c

168 Here, we found that the beta-adrenergic agonist isoproterenol induced mature beta-adr

169 uce LTP, but the addition of either the beta-adrenergic agonist isoproterenol or the cAMP analog 8-br

170 In both rat and human strips, the full beta-adrenergic agonist isoproterenol raised cAMP levels by >

171 Stimulation of LQT2 cells with beta-adrenergic agonist isoproterenol resulted in prolongatio

172 Membrane-permeable 8-bromo-cAMP and the beta-adrenergic agonist isoproterenol significantly reversed

173 ing the chimera (beta2AR-Rfz1) with the beta-adrenergic agonist isoproterenol stimulated stabilizatio

174 els (including PGE2, forskolin, and the beta-adrenergic agonist isoproterenol) can inhibit P2Y recept

175 ptic stimulation in the presence of the beta-adrenergic agonist isoproterenol, a combination that ind

176 initiating rapid endocytosis of B2ARs by the adrenergic agonist isoproterenol, we observed bright "pu

177 ates the vasorelaxation response to the beta-adrenergic agonist isoproterenol, without affecting endo

178 reatment with a single high dose of the beta-adrenergic agonist isoproterenol.

179 ed to describe myocyte responses to the beta-adrenergic agonist isoproterenol.

180 ted the Mg(2+) extrusion induced by the beta-adrenergic agonist isoproterenol.

181 levels that were pre-elevated with the beta-adrenergic agonist isoproterenol.

182 a-adrenergic blocker metoprolol and the beta-adrenergic agonist isoproterenol.

183 ose-dependent inotropic response to the beta-adrenergic agonist isoproterenol.

184 ts caused by high concentrations of the beta-adrenergic agonist isoproterenol.

185 it was blocked in cells pretreated with beta-adrenergic agonist isoproterenol.

186 myocytes following stimulation with the beta-adrenergic agonist isoproterenol.

187 Intraperitoneal injection of a beta-adrenergic agonist (isoproterenol) enhances SIRT2 expres

188 n VSMC as profoundly as the G(s)-linked beta-adrenergic agonist, isoproterenol (ISO), but in a transi

189 t, clonidine (CLON; 0.6 mg/kg BW), or a beta-adrenergic agonist, isoproterenol (ISO; 0.2 mg/kg BW) al

190 s PKA activities at the SR induced by a beta-adrenergic agonist, isoproterenol, and subsequently bloc

191 Pretreatment with a beta-adrenergic agonist, isoproterenol, or a cAMP analog amel

192 activated by parathyroid hormone or the beta-adrenergic agonist, isoproterenol.

193 attenuated contractile responses to the beta-adrenergic agonist, isoproterenol.

194 Apical adrenergic agonists, isoproterenol and epinephrine (10(-

195 tion stimulated by cholinergic and alpha(1D)-adrenergic agonists, it does not play a role in epiderma

196 A beta3-adrenergic agonist known to activate metabolic heat prod

197 shown that combinations of long-acting beta2-adrenergic agonists (LABAs) and long-acting muscarinic a

198 These findings suggest that beta-adrenergic agonists lead to functional benefit in the Co

199 Stimulation with 2 adrenergic agonists led to sudden cardiac death of all m

200 Encephalopathy severity and adrenergic agonist medication exposure were the primary

201 n inhaled corticosteroid/long-acting beta(2)-adrenergic agonist medications in African American asthm

202 The alpha1-adrenergic agonist methoxamine increased NKCC1 activity

203 lpha1 was reversed with the selective alpha1-adrenergic agonist midodrine, the inappropriate heat los

204 The adrenergic agonists norepinephrine and phenylephrine ind

205 rolonged fasting, and administration of beta-adrenergic agonists (norepinephrine and CL-316243).

206 A beta(1)-adrenergic agonist, norepinephrine (10(-9)-10(-6) m), in

207 s study evaluated the effect of various beta-adrenergic agonists on (18)F-FDG uptake in brown adipose

208 o investigate the actions of alpha- and beta-adrenergic agonists on Na+-K+ pump current.

209 his work were to study the effects of alpha2-adrenergic agonists on the inflammatory response in vivo

210 d to study the effect of salbutamol, a beta2-adrenergic agonist, on synaptic structure and function.

211 state was observed after treatment with beta-adrenergic agonist or with coexpression of phosphomimeti

212 cyte secretion in response to secretin, beta-adrenergic agonists, or changes in [HCO(3)(-)](i), respe

213 An adrenergic agonist, para-aminoclonidine, inhibited forsk

214 gonist carbachol (10(-4) M), or the alpha(1)-adrenergic agonist phenylephrine (10(-4) M), and peroxid

215 myocytes treated for 48 h with the alpha(1)-adrenergic agonist phenylephrine (PE) had an 80% increas

216 cations (separated by 5 min) of the alpha(1)-adrenergic agonist phenylephrine (PE) in combination wit

217 The alpha-adrenergic agonist phenylephrine (PE) increased tissue s

218 sfected HepG2 cells (TFG2) with the alpha(1)-adrenergic agonist phenylephrine (PE) significantly acti

219 The alpha(1)-adrenergic agonist phenylephrine (PE; 100 micrometer) al

220 The selective alpha1 adrenergic agonist phenylephrine had no effect on membra

221 The adrenergic agonist phenylephrine increased instantaneous

222 Moreover, infusions of the selective alpha1 adrenergic agonist phenylephrine into the basal forebrai

223 In contrast, contractions to the alpha1-adrenergic agonist phenylephrine or the thromboxane (TX)

224 cholinergic agonist carbachol, the alpha(1D)-adrenergic agonist phenylephrine, or EGF.

225 > 0.05) during local administration of alpha-adrenergic agonists (phenylephrine (PE), alpha(1); cloni

226 cts of angiotensin II (Ang II) and the alpha-adrenergic agonist, phenylephrine (PE), on cardiac energ

227 n animals were treated with either an alpha1-adrenergic agonist, phenylephrine (PHE; 0.5 mg/kg BW), a

228 erm intravenous administration of an alpha-1 adrenergic agonist, phenylephrine, and a beta-1 adrenerg

229 reas treatment of hepatocytes with an alpha1 adrenergic agonist, phenylephrine, enhanced hepatocyte p

230 nhibition of Ca(2+) channel activity by beta-adrenergic agonists/PKA also requires this rigid linker

231 yocytes from GRK5-knockout (KO) mice to beta-adrenergic agonists, pretreatment of GRK5-KO cardiomyocy

232 We have found that alpha-2 adrenergic agonists prevent the PC/RS neurotoxic side ef

233 These studies indicate that cAMP and beta-adrenergic agonists produce distinct short and long term

234 t that isoproterenol (ISO) and related beta2-adrenergic agonists reacidify lysosomes in PSEN1 Knock o

235 eatment with xylazine or UK14304, two alpha2-adrenergic agonists, reduced neutrophil migration by 60%

236 modulation of the hypnotic effect of alpha-2 adrenergic agonists remains uncertain.

237 suggest that the suppressive effect of beta-adrenergic agonists requires the presence of the P-loop

238 Administration of beta-adrenergic agonist restored the expression of presynapti

239 Beta-adrenergic agonists restored AFR in rats exposed to 8% O

240 re small and insensitive to insulin and beta-adrenergic agonists resulting in reduced adipocyte lipid

241 because intra-hippocampal injections of beta-adrenergic agonists reversed cell death.

242 ure resulting from the addition of the beta2-adrenergic agonist salbutamol to the anticholinesterase

243 The beta-adrenergic agonists salbutamol and ephedrine have proven

244 Dose-response curves for both adrenergic agonists showed that HC increased linearly as

245 proterenol, a rapidly acting peripheral beta-adrenergic agonist similar to adrenaline, to induce sens

246 travenous infusions of isoproterenol, a beta-adrenergic agonist similar to adrenaline.

247 Beta-adrenergic agonists stimulate cardiac contractility and

248 alpha(1D)-Adrenergic agonists stimulate eNOS to produce NO, leadin

249 Here we identify the mechanism by which beta-adrenergic agonists stimulate voltage-gated calcium chan

250 mine and metaraminol, three selective alpha1-adrenergic agonists, stimulate Ip in a similar manner to

251 el role for TGF-beta1 in impairing the beta- adrenergic agonist-stimulated alveolar fluid clearance i

252 lates both peripheral vascular tone and beta-adrenergic agonist-stimulated cardiac contractility, pre

253 ulated above basal secretion, whereas alpha1-adrenergic-agonist-stimulated protein secretion was incr

254 action by which phenylephrine, an alpha(1) -adrenergic agonist stimulating intracellular D-myo-inosi

255 a to alpha(1C) I-II loop and eliminated beta-adrenergic agonist stimulation of Ca(V)1.2 current.

256 ed basal lipolysis that is resistant to beta-adrenergic agonist stimulation, and are cold-sensitive e

257 asured in response to cholinergic and alpha1-adrenergic agonist stimulation.

258 Intrathecal administration of alpha(2) adrenergic agonists, such as clonidine, is capable of al

259 The beta-adrenergic agonist terbutaline produced changes in AQP5

260 ial cells were treated with cAMP or the beta-adrenergic agonist terbutaline, a biphasic AQP5 response

261 Reaction of the medically relevant alpha-adrenergic agonists tetrahydrozoline and idazoxan produc

262 cell stimulation with isoproterenol, a beta-adrenergic agonist that activates adenylyl cyclase, enha

263 application of isoproterenol (1 muM), a beta-adrenergic agonist that activates PKA, significantly red

264 e efficacy of midodrine, a selective alpha-1 adrenergic agonist that decreases venous capacitance, in

265 Clonidine is a partial alpha 2 adrenergic agonist that has a variety of different actio

266 fter administration of isoproterenol, a beta-adrenergic agonist that increases circulating levels of

267 ntly, 3OST2 transcription is blocked by beta-adrenergic agonists that activate the pineal melatonin f

268 Pharmacological treatment with a beta-adrenergic agonist to stimulate lipolysis evoked a 3-fol

269 nervation of the gland nor the ability of an adrenergic agonist to stimulate NAT activity was reduced

270 ase pathway, attenuating the ability of beta-adrenergic agonists to act following stimulation of cell

271 posure to cognitive novelty and/or oral beta-adrenergic agonists to lessen the effects of Abeta accum

272 specific impairment in the capacity of beta2-adrenergic agonists to promote lipolysis in subcutaneous

273 both beta(3)-selective and nonspecific beta-adrenergic agonists to stimulate lipolysis is markedly c

274 ays the effects of chronic exposure to beta3-adrenergic agonist treatment, which also results in impr

275 The stimulation of lipolysis by beta-adrenergic agonists triggers rapid phosphorylation of pe

276 similar sensitivity to the specific alpha(2)-adrenergic agonist UK 14,304, to serotonin, and to angio

277 ole and mechanisms of action of the alpha(2)-adrenergic agonist UK14,304 in the regulation of growth

278 Epinephrine and the selective alpha2-adrenergic agonist UK14304 reduced insulin secretion and

279 as relevant in the context of detecting beta-adrenergic agonists use in animals.

280 ing promotes anti-nociception, with alpha(2)-adrenergic agonists used clinically.

281 With continuous exposure to beta2-adrenergic agonists, vascular tissue becomes desensitize

282 ere stimulated with cholinergic and alpha(1)-adrenergic agonists, vasoactive intestinal peptide (VIP)

283 s by its alpha1 (alpha1) and alpha2 (alpha2)-adrenergic agonist vasopressor actions.

284 A beta3 adrenergic agonist was administered for 2 weeks in Wista

285 ion stimulated by phenylephrine, an alpha(1)-adrenergic agonist, was measured with a fluorescence ass

286 ctural similarities of NNK with classic beta-adrenergic agonists, we tested the hypothesis that NNK s

287 parameters and inotropic response to a beta-adrenergic agonist were measured in isolated trabecular

288 both cold tolerance and response to a beta3-adrenergic agonist were similar in both genotypes.

289 Additionally, contractile responses to alpha-adrenergic agonists were greatly attenuated.

290 Increasing doses of dobutamine, a beta1-adrenergic agonist, were administered to conscious unres

291 d not attenuate stimulatory response to beta-adrenergic agonists when reconstituted heterologously wi

292 avenous injection of phenylephrine (an alpha-adrenergic agonist which raises blood pressure).

293 otropic and lusitropic tachyphylaxis to beta-adrenergic agonist, which likely contributes to its prot

294 extrarenal factors such as insulin and beta-adrenergic agonists, which stimulate the movement of K f

295 ogenous NO donor), and isoproterenol (a beta-adrenergic agonist whose vasodilator effect stems from t

296 y stimulation of isoproterenol (ISO), a beta-adrenergic agonist with a peak at approximately 12 hours

297 (3)(-)/CO(2), cholinergic agonists, and beta-adrenergic agonists, with or without selected inhibitors

298 Mice chronically fed a beta-adrenergic agonist without EE were protected from hippoc

299 e of whether regular use of an inhaled beta2-adrenergic agonist worsens airflow and clinical outcomes

300 and systemic administration of the alpha(2)-adrenergic agonist xylazine, all of which have been show